Insecticidal proteins from plants and methods for their use - US12595488B2

USPTO granted Patent No. 12,595,488 B2 to Pioneer Hi-Bred International, Inc. covering compositions and methods for producing insecticidal proteins derived from plants. The patent claims 10 protected compositions including nucleic acid sequences, expression vectors, and transformed organisms useful for controlling Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran, and nematode pest populations.

Sterile genes and related constructs and applications thereof

USPTO granted patent US12595489B2 to SINOBIOWAY BIO-AGRICULTURE GROUP CO. LTD. covering isolated polynucleotides, polypeptides, and recombinant DNA constructs for regulating plant sterility, with 3 claims allowed under CPC classification C12N 15/829. The patent, which issues from application 17597380 filed July 5, 2019, provides intellectual property protection for sterility gene technology in plants.

Rapamycin resistant cells

Seattle Children's Hospital has been granted US Patent 12595492B2 for rapamycin resistant cell compositions and methods. The patent covers proteins expressed in host cells to confer rapamycin resistance, with applications in modulating cell signaling and selective cell expansion. The patent contains 32 claims with six named inventors including Andrew M. Scharenberg and David J. Rawdings.

Roche UBE3A Angelman Syndrome Oligonucleotide Patent Granted

USPTO granted patent US12596118B2 to Hoffmann-La Roche Inc. covering oligonucleotides capable of inducing paternal UBE3A expression for treatment of Angelman syndrome. The patent, listing 9 inventors, contains 30 claims targeting the SNHG14 long non-coding RNA downstream of SNORD109B. This is a pharmaceutical composition patent within the oligonucleotides therapeutic space.

DISARM Therapeutics patent, SARM1 inhibitors, neuroprotection

DISARM Therapeutics patent, SARM1 inhibitors, neuroprotection

Treatment of tumors with miRNA targeting CDK4/CDK6

USPTO granted patent US12595483B2 to the Institute for Cancer Research of Fox Chase Cancer Center for miRNA mimics targeting CDK4 and/or CDK6 for tumor treatment, including colon cancer. The patent covers modified oligonucleotides comprising miRNA and methods for administering the compositions to patients.

Vasopressin-2 receptor antagonist peptides and uses thereof

The USPTO has granted Patent US12595288B2 to Commissariat à l'Énergie Atomique et aux Énergies Alternatives covering vasopressin-2 receptor antagonist peptides. The patent protects peptide sequences with at least 80% amino acid identity to SEQ ID NO. 1, with specific modifications at variable positions enabling therapeutic applications. The grant includes 14 claims.

Methods to Decrease Impurities from Recombinant Protein Manufacturing Processes

The USPTO granted Patent US12595294B2 to Hoffmann-La Roche Inc. on April 7, 2026. The patent covers methods for reducing non-aggregate produce-related impurities (NAPRIs) in buffered solutions of monoclonal antibodies using synthetic depth filters. Inventors are Marc Pompiati and Christoph Feistl, with 15 claims in the granted patent.

Anti-NGF Antibody and Antigen-Binding Fragment Patent Grant

USPTO granted Patent US12595298B2 to XIYUAN ANJIAN MEDICINE (SHANGHAI) CO., LTD. for an anti-NGF antibody and its antigen-binding fragment, covering the preparation method and therapeutic applications for NGF-mediated diseases. The patent includes 6 claims and was filed on August 2, 2021.

Fc Variants and IL-8 Antibodies Patent Grant

USPTO granted patent US12595299B2 to Chugai Seiyaku Kabushiki Kaisha covering Fc region variants with improved antigen binding in ion concentration-dependent manner, Fc variants with decreased binding to pre-existing anti-drug antibodies, and novel IL-8 antibodies for pharmaceutical use. The patent contains 17 claims and covers molecules derived from antibody engineering technology.